Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen, Inc.
New findings in cancer treatment described from the United States
May 8th, 2006
Data on cancer treatment are outlined in reports from the United States. Study 1: Fully human monoclonal antibodies to hepatocyte growth factor show therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. "e-Met is a well-characterized receptor tyrosine kinase for hepatocyte growth factor (HGF). Compelling evidence from studies in human tumors and both cellular and animal tumor models indicates that signaling through the HGF/c-Met pathway mediates a plethora of normal cellular activities, including proliferation, survival, migration, and invasion, that are at the root of cancer cell dysregulation, tumorigenesis, and tumor...
Source: Biotech Week (2006-05-08)
|
